ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

In-Stock Modified PseudoUridine Materials to Support Demanding Applications

New York, United States - BOC Sciences supplies in-stock modified pseudoUridine materials, such as 2-thiopseudoUridine and 1-MethylpseudoUridine, to support mRNA therapeutics and many other associated studies. As a recognized chemical manufacturer, BOC Sciences is dedicated to providing a full range of pseudoUridine products and related services for worldwide customers with years of RNA modification experience and high-end technologies. 

Post-transcriptional modifications were known to be crucial in regulating the structure, stability, and function of RNA molecules. For example, research findings indicate that nucleoside modification is an effective approach to enhancing the stability and translational capacity of mRNA with reduced immunogenicity in vivo. In addition, these improved properties conferred by pseudoUridine make such mRNA a promising tool for both gene replacement and vaccination. Modified pseudoUridine, including 2-thiothymidine and 4-thiopseudoisocytidine, can solidify the thermal stability of triplex-DNA. Nevertheless, many ongoing studies utilizing modified nucleosides have yielded promising research outcomes.

BOC Sciences, the largest supplier of pseudoUridine globally, can provide top-qualified pseudoUridine modification services and featured pseudoUridine products based on its well-established technical platform. It reserved a variety of modified pseudoUridine ready to use for effective epigenetic therapy development based on RNA modifications, including 2-thiopseudoUridine, N1-cyanomethyl pseudoUridine, and 3-(3-amino-3-carboxypropyl) pseudoUridine. If customers can't find the products they are looking for, the seasoned experts of BOC Sciences can synthesize specific pseudoUridine according to the project needs.

The marketing manager of BOC Sciences said, "Our team of scientists can use flexible technologies to synthesize and modify pseudoUridine for clients from both research and industry with more than 20 years of academic know-how and experience. And our products and services are supported and ensured by our commitment to premium quality. We're a reliable partner to take care of your inquiry individually for technical and scientific questions through direct communication with our experts."  

About BOC Sciences

BOC Sciences has become the largest supplier of pseudoUridine in the world in terms of production capacity. Its annual output of pseudoUridine is currently over 500 kg. With years of experience in pseudoUridine and its derivatives, the capability of BOC Sciences in synthesis, modification, scale-up, and innovative purification strategies has been generally acknowledged. In the future, BOC Sciences will continue its introduction of pseudoUridine and derivatives involved in mRNA vaccine and drug research in the hope of promoting these exciting research activities.

Media Contact

Company Name
BOC Sciences
Contact Name
Alex Brown
Country
United States
Website
https://nucleotech.bocsci.com/

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.